Takeda Pharmaceutical Company Limited

Dyax Corporation

Syntonix Pharmaceuticals, Inc.

Biogen Hemophilia Inc.

Bioverativ Therapeutics Inc.

Christopher TenHoor

Daniel J Sexton

Malini Viswanathan

Ryan Faucette

Burt Adelman

Jon A Kenniston

Robert Charles Ladner

Aaron Sato

Alan J Bitonti

Clive R Wood

Kevin McDonnell

Andrew Nixon

Jennifer A Dumont

Arumugam Muruganandam

Gregory P Conley

Yung Chyung

Liming Liu

James Stattel

Ryan Iarrobino

Joseph Biedenkapp

James McGivney

Greg Conley

Kevin Mcdonnell

Clive Wood

The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Assays for determining plasma kallikrein system biomarkers

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Antibodies which bind Fc receptors (FcRn)

The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Methods of determining levels of cleaved and/or intact kininogen

Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies

Fc receptor antibodies and methods of use thereof

Methods of producing antibodies to neonatal Fc receptor (FcRn)

Human neonatal Fc receptor antibodies and methods of use thereof

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Antibodies to FeRn and uses thereof

Fc receptor binding proteins

Growing community of inventors

Hopkinton, MA, United States of America

Christopher TenHoor